Position in VCEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$6,176,991
+$1,928,525 QoQ
Shares Held
138,840
+5.1% QoQ
Ownership
0.271%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#62
of 317 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RICE HALL JAMES & ASSOCIATES, LLC holds $259,930,953 across 19 Biotechnology names. VCEL ranks #13 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
270,052 | $85,360,736 | |
| 2 | ASND |
Ascendis Pharma A/S
|
148,644 | $39,646,327 | |
| 3 | VRDN |
Viridian Therapeutics, Inc.\DE
|
1,175,906 | $21,601,393 | |
| 4 | ACAD |
Acadia Pharmaceuticals Inc
|
618,887 | $15,657,841 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
248,224 | $14,203,377 | |
| 6 | TSHA |
Taysha Gene Therapies, Inc.
|
1,992,229 | $13,567,079 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
110,673 | $12,956,488 | |
| 8 | URGN |
UroGen Pharma Ltd.
|
300,650 | $11,063,920 |
All Filings in VCEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,176,991 | 138,840 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $4,248,466 | 132,063 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,680,183 | 129,969 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $313,315 | 9,956 | Shares | Sole | 2025-10-16 | |
| No filing history on record for this holder in this stock. | ||||||